Testing chemotherapy with or without extra cancer medicines for nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This Phase 2 study compares standard chemotherapy (gemcitabine plus cisplatin) against the same chemotherapy plus pembrolizumab and bevacizumab. It aims to see which combination works better for EBV-positive nasopharyngeal cancer before any prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your legal representative) can sign written consent for the study.
- You are 21 years or older and have non-keratinizing nasopharyngeal cancer confirmed by lab testing.
- Your cancer must be EBV-positive, and your tumor must be measurable on scans.
- Your cancer stage must be III (with limited specific exceptions) or stage IVA, and you should not have had any prior cancer treatment.
- Your overall health/function should be good (ECOG score 0–1), and your organs must work well enough for treatment.
- You must be able to give blood for required study tests, and follow pregnancy/contraception rules if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of an immunotherapy drug (tislelizumab) plus standard chemoradiotherapy for people with advanced nasopharyngeal carcinoma. It aims to find out if this combination is more effective than standard care alone.
This trial tests a treatment approach for people with locally advanced nasopharyngeal cancer using their blood EBV DNA level (a cancer-related virus marker). It may help doctors choose and adjust therapy based on how much of this marker is in your blood after standard treatment.
This trial tests a new combination of treatments—a targeted drug that delivers cancer-killing medicine directly to tumor cells, an immunotherapy that helps your immune system fight cancer, and standard chemoradiation—for people with advanced nasopharyngeal cancer. The goal is to see if this combination works better than standard treatment alone.
This trial tests a “choose the best treatment” approach for people with nasopharyngeal cancer (NPC) that is linked to EBV (a common virus). By matching treatment to your EBV and cancer features, the study aims to improve outcomes while tracking safety.
This trial tests a combination of chemotherapy and immunotherapy (pembrolizumab) given before and after surgery for nasopharyngeal cancer that has come back locally. The goal is to see if this approach can control the cancer and improve outcomes for patients who can't have standard re-treatment.
This trial tests whether giving an immunotherapy drug called adebrelimab, based on levels of EBV DNA in the blood, can help people with advanced nasopharyngeal cancer. It is for those who have finished initial chemotherapy and still have signs of the virus or stable disease.
Hear when a new Nasopharyngeal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.